Disease Landscape and Forecast Insights

The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the…

Obesity is a significant public health concern in the major pharmaceutical markets under study and is growing into an epidemic. Despite the prevalence of the disease, few drugs are available to…

The hospital-treated gram-negative infection (GNI) market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-resistant (MDR) pathogens…

Market Outlook Atypical antipsychotics—the cornerstone of schizophrenia treatment—are available as oral and long-acting depot formulations in the United States. Many of the oral atypical…

The maturing but highly lucrative market for MSDMTs continues to fragment as new entrants propel ongoing shifts in a complicated treatment algorithm. Roche/Genentech’s Ocrevus will intensify…

The treatment of both solid and hematological cancers is associated with a wide range of serious side effects, including chemotherapy-associated neutropenia and anemia, nausea and vomiting, and…

Immune biologics such as TNF-alpha inhibitors are among the most commercially successful biopharmaceutical products in the world, presenting a lucrative opportunity for companies to develop…

Osteoarthritic (OA) pain represents the second largest segment of the chronic pain market, a market which is expected to grow, driven by the aging population and increasing prevalence of obesity…

Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in the early stages of the disease, today’s treatment paradigm is suboptimal owing to the considerable pill…

Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed in recent years by the identification of BRAFmutations and the development of BRAF and MEK…

Diabetic nephropathy (DN) refers to kidney disease caused by diabetes. DN is a leading cause of chronic kidney disease (CKD), and is associated with high morbidity, mortality, and cost. Use of…

Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to grow. Existing agents fail to…